I am a GU medical oncologist at City of Hope Comprehensive Cancer Center, music enthusiast, and proud dog father. Tweets are my own.
Duarte, CA
Joined February 2020
- Tweets327
- Following333
- Followers708
- Likes780
Alex Chehrazi-Raffle, MD retweeted
CD70. ENPP3. HPK1. GPR65. All promising targets in #kidneycancer, but what is know about their prognostic/predictive value? Are they enriched in pts with angiogenic or immunogenic profiles? My brilliant @cityofhope postdoctoral fellow @RWinayak takes aim at these questions in his #ESMO26 poster. Do stop by!
@AndreaNecchi @tompowles1 @brian_rini @DrChoueiri @shilpaonc @apolo_andrea @TDorffOnc @neerajaiims @PGrivasMDPhD @g_procopio_ @gbanna74 @ravikanesvaran @OncoAlert
Excited to share our #ESMO26 abstract on emerging targets in mRCC. Analysis of 2,134 RCC transcriptomes identified immunogenic (GPR65/HPK1) and angiogenic (ENPP3/CD70) programs linked to improved outcomes with IO vs non-IO therapy, informing future combination strategies.
Alex Chehrazi-Raffle, MD retweeted
Important data from #ESMO2026 in #mCRPC:
🧬 56% of HRR alterations detected by liquid biopsy were predicted to originate from clonal hematopoiesis (CH).
⚠️ Patients with CH-only HRR alterations did not appear to benefit from PARPi monotherapy.
Distinguishing CH from tumor-derived mutations is critical for treatment selection. #ProstateCancer @EAntonarakis @urotoday @PCF_Science @OncoAlert
Alex Chehrazi-Raffle, MD retweeted
Our study is now published in @JAMANetworkOpen!
We mapped 436 bladder cancer clinical trials across US counties and examined associations with incidence, mortality, & social vulnerability. Among 3,145 US counties, 77.3% had no bladder cancer trials! 🧵⬇️
jamanetwork.com/journals/jam…
Alex Chehrazi-Raffle, MD retweeted
On behalf of a terrific team of investigators (@BGarmezy @KotechaMD @DrKarieRuncie @BraunMDPhD et al), very proud to present the 1st data for XmAb819, a first-in-class ENPP3 x CD3 bispecific in patients with #kidneycancer. We have long needed new targets beyond #VEGF-axis & checkpoint inhibition. If you are at the @AACR @theNCI @EORTC #Targets25, come visit our poster in the session starting at noon today - if not, read below ... (1/8)
Alex Chehrazi-Raffle, MD retweeted
First glimpses into saruparib in PETRANHA by @AzadOncology Surprised by the comparable rates of anemia. Has encouraging initial activity but hard to differentiate from ARPI alone given study design. Await P3 data
Hot off the presses 📰 our @JCOPO_ASCO study shows ctDNA can detect MRD in GCTs, outperforming STMs. Huge multi-center #TeamScience effort—proud of this crew! 💪 @rebeccahassoun @ReubenBenDavid1 @nabiladra @DrJohnSfakianos @TDorffOnc @NateraGenetics
👉ascopubs.org/doi/full/10.120…
Alex Chehrazi-Raffle, MD retweeted
A must-read editorial in @EUplatinum by @NazliDizman @EbrahimiHedyeh and @arafflemd on the current state of non-clear cell RCC!
@OncoAlert @DrChoueiri @DrYukselUrun @MikeSerzanMD #KidneyCancer #oncology #MedX @montypal
👉doi.org/10.1016/j.eururo.202…
Alex Chehrazi-Raffle, MD retweeted
Terrific job @brian_rini & @tompowles1. Particularly enjoyed the discussion around #neoadjuvant design. Folks, if you are planning a neoadjuvant study in #kidneycancer please consider getting in touch with #AxelBex & his colleague @grantissimus. They have put lots of thought into study methodology & endpoints in this setting. At #KCRS25, one of my favorite moments was sitting down with them @WesleyYipMD to hone endpoints in a study Wes is designing with his @ASCO CDA.
🚨Introducing the IMPACT series. In these episodes, The Uromigos conduct deep dives with their peers on papers that influenced their careers, approaches to clinical care and research direction among other points of interest. In this episode Dr. Axel Bek focuses on impactful RCC trials, consolidative approaches, and what can impact an academic career.
🎙️ GU Oncology Now: buff.ly/fGBbGLW
🍎 Apple Podcasts: buff.ly/zJvHm78
🎧Spotify: buff.ly/pmGmZgl
Alex Chehrazi-Raffle, MD retweeted
Incredibly honored to be featured on the cover of the June issue of @CD_AACR. This work supported by @CRUKresearch as a part of the MUTOGRAPHS Grand Challenge Awards and the @theNCI F32 fellowship encompasses efforts decades in the making spearheaded by my mentor Prof. Allan Balmain. Our finding underscore a critical issue that is deeply under-appreciated concept in the cancer prevention and control policy and research, which is the importance of cancer promotion as a tumorigenic mechanism. Specifically, initiated tissue-resident cells bearing driver mutations can remain latent for a long period of time awaiting a signal to divide and become “cancer”. Thus, there is a critical need to better understand the mechanisms of promotion (which include some that we investigated like obesity and inflammation) but also many others that we do not yet understand or appreciate. Excited for the next phase of this work being funded by the @CRUKresearch PROMINENT and @NIH_CommonFund DP5 awards to better understand the mechanism of cancer promotion.
Read the paper featured on the cover this month: Long-Term Latency of Highly Mutated Cells in Normal Mouse Skin Is Reversed by Exposure to Tumor Promoters and Chronic Tissue Damage brnw.ch/21wTgGB
By @yunroseli, Allan Balmain, and colleagues @cityofhope @UCSF
Alex Chehrazi-Raffle, MD retweeted
1/ Huge thanks to all collaborators, but especially to @arafflemd , great friend and mentor, for the opportunity to contribute to this multicenter study on HDCT in refractory/recurrent #GCT!
🚨Check out our multicenter study that compared the most commonly used high-dose chemo regimens for refractory #GCT. HUGE thanks to our collaborators at @UCSFCancer @UCDavisHealth @UCLAHealthJCCC, and @mzugman @montypal @TDorffOnc @matthew_mei for their leadership & support! 🙏🏼
🚨Check out our multicenter study that compared the most commonly used high-dose chemo regimens for refractory #GCT. HUGE thanks to our collaborators at @UCSFCancer @UCDavisHealth @UCLAHealthJCCC, and @mzugman @montypal @TDorffOnc @matthew_mei for their leadership & support! 🙏🏼
Multicenter analysis of high-dose chemotherapy regimens for the treatment
of pts with refractory or recurrent GCTs in @ESMO_Open. 111 pts retrospectively analysed, similar results with CE vs TICE, potential benefit with TICE in higher risk disease. esmoopen.com/action/showPdf?…
Alex Chehrazi-Raffle, MD retweeted
Had a chance to celebrate @arafflemd's new paper in @ESMO_Open (co-first auth: @mzugman) over lunch today at @SWOG! This multicenter collaboration exploring HDCT regimens (CE/TICE) required years of effort in which he pooled data across @cityofhope, @UCSFCancer, @uscnorris & @UCD_Cancer. He was asked by @cityofhope leadership to build our program in #testicularcancer & has done a simply phenomenal job in this regard.
Alex Chehrazi-Raffle, MD retweeted
🎖️Trainees in oncology and across all fields of medicine! Do not miss this manuscript on how to effectively respond to reviewer comments!
Thanks @VickersBiostats @redunndant @cgratzke @MRoupret @Albert0Briganti et al. @EUplatinum @EurUrolFocus @EurUrolOncol 🙏
@OncoAlert @ASCOTECAG @IMG_Oncologists @HemOncFellows @HemOncWomenDocs #MedEdCoP #Meded #OncTwitter @YaleIMed @ASCO @ASH_hematology
Alex Chehrazi-Raffle, MD retweeted
Best talk I have been to all year was right here at @cityofhope at our GU retreat (organized by @arafflemd). @yunroseli @COH_RadOnc just delivered a tour de force highlighting her work in #prostatecancer w @TDorffOnc et al focused on fasting interventions & other metabolic strategies. Well executed @NIH funded studies w rich correlatives; recently funded effort looking at #GLP1 alongside @JuneWRhee thanks for a massive @American_Heart grant. Keep up the amazing work, Rose! Proud of you.
Alex Chehrazi-Raffle, MD retweeted
🧵 1/7 Newly published @JCO_ASCO #OncologyAdvances! Our study explores how insurance status affects survival outcomes for patients with metastatic renal cell carcinoma (mRCC) receiving first-line systemic therapy. Read here: doi.org/10.1200/OA.24.00015
Alex Chehrazi-Raffle, MD retweeted
Federal #kidneycancer research funding drops from $50 million to ZERO after 57% cut to CDMRP. All but 12 of the 35 disease research programs saw funding eliminated for 2025, including the Kidney Cancer Research Program. More about the impact on our blog. bit.ly/4hoXnCq
Alex Chehrazi-Raffle, MD retweeted
I am so proud! @KahlaSalgia has one of the kindest hearts I have ever met among any of my students. It was an honor to work with her & look forward to seeing her continue to rise with my dear friends at @HarborUCLA! @arafflemd @TDorffOnc @DrMvandenBrink @AbhiTrip87 @AlexisLevee @DrAryaAmini @charlesbnguyen
Congratulations @KahlaSalgia for matching @HarborUCLA #proud! Amazing journey! @MeghanSalgia @NickSalgia @montypal @cityofhope @WesternU_COMP
Alex Chehrazi-Raffle, MD retweeted
🚀 First-Time at @ASCO #GU25? Here’s What You Need to Know! 🎯
📅 Plan ahead! This is more intimate than ASCO, so take advantage of smaller sessions to connect with experts
💬 Engage with presenters!
📲 Don’t just attend, participate! Share insights on #GU25, join discussions, and connect beyond the meeting
🔎 Poster sessions = hidden gems! Great discussions and new collaborations start here
Alex Chehrazi-Raffle, MD retweeted
We are getting awfully close to a full house for #SoCalGU25! Come join us at the @BalboaBayClub on Friday, Feb 28, for full day of #clinicaltrial discussions on #GU cancers. We look forward to hosting speakers from @UCIrvine, @UCLAHealth, @USC_Urology, @cityofhopeoc, @LLU_Urology, @UCSDCancer & more! Fellows - we are looking for posters! Special guest @AndreaNecchi doing our keynote & terrific panelists including @TDorffOnc @jgong15 @siadaneshmand @WesleyYipMD @arafflemd @AbhiTrip87 @KidneyCancerDoc @DrTylerStewart & so many more! Register here:
cme.cityofhope.org/content/2…
